BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Setbacks in Texas and elsewhere put Republicans' redistricting hopes in doubt as key deadlines loom - 2Guaranteeing Quality Medical care with Federal medical care Benefit Plans.
- 3Pick Your Top Method for starting the Morning
- 4Vacation destinations in America
- 5Two reportedly killed as Israel attacks Hezbollah targets in Lebanon
- Figure out How to Clean and Really focus on Your Lab Jewel
- Vote in favor of the pasta that makes good dieting charming!
- These are the Fastest Italian Sports Cars
- Inconceivable Spots To Stargaze All over The Planet
- Purdue Pharma's deal means money for some victims, end of Purdue company name. Here's what to know
- From Loner to Force to be reckoned with: Individual Accounts of Change
- Discovering a true sense of harmony: Contemplation and Care Practices
- The Best Computer games for Multiplayer Fun
- Astounding Treehouses All over the Planet
